Dr. Pollack is currently serving as the 12th dean of the University at Buffalo School of Pharmacy and Pharmaceutical Sciences. His research focuses on how drugs and toxicants affect the central nervous system, and he has made significant contributions to the understanding of opioid tolerance. He has published in more than 150 academic journal articles and delivered 45 research presentations. He is co-founder of Qualyst Inc., a company developing in vitro hepatic models to predict the effect of drugs and other compounds on the human liver. Pollack also holds a patent for a method and apparatus that rapidly determines ligand protein binding using charcoal absorption.